Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy

Ann Hematol. 2015 Apr;94(4):687-9. doi: 10.1007/s00277-014-2214-x. Epub 2014 Sep 12.

Authors

Junya Kuroda¹, Shinsuke Mizutani, Yuji Shimura, Saori Maegawa, Hisao Nagoshi, Yoshiaki Chinen, Shotaro Tatekawa, Taku Tsukamoto, Yoshimi Mizuno, Mio Yamamoto-Sugitani, Tsutomu Kobayashi, Yosuke Matsumoto, Shigeo Horiike, Masafumi Taniwaki

Affiliation

¹ Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan, junkuro@koto.kpu-m.ac.jp.

PMID: 25209844
DOI: 10.1007/s00277-014-2214-x

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Intravenous
Aged
Aged, 80 and over
Antineoplastic Agents / administration & dosage*
Boronic Acids / administration & dosage*
Bortezomib
Dexamethasone / administration & dosage
Disease Progression
Drug Resistance, Neoplasm
Female
Humans
Injections, Subcutaneous
Male
Multiple Myeloma / drug therapy*
Multiple Myeloma / pathology
Pyrazines / administration & dosage*

Substances

Antineoplastic Agents
Boronic Acids
Pyrazines
Bortezomib
Dexamethasone